The "delayed Onset" of Antipsychotic Action--an Idea Whose Time Has Come and Gone

Overview

Journal J Psychiatry Neurosci

Specialty Psychiatry

Date 2006 Apr 1

PMID 16575424

Citations 43

Authors

Ofer Agid

Phillip Seeman

Shitij Kapur

Affiliations

Soon will be listed here.

Abstract

For years, it has been known that the "onset" of the antipsychotic response is "delayed," and this notion is expressed in many major textbooks, informs clinical decisions and has even led to the search for biological markers responsible for this delayed onset. But is the onset of antipsychotic action really delayed? In this review, we bring together data from several recent studies of antipsychotic drugs that show that the onset of the antipsychotic effect is within the first day; the effect is distinguishable from behavioural sedation; is specific to antipsychotic drugs; is seen with oral and parenteral preparations; and is seen with typical and atypical antipsychotics. More anti- "psychotic" improvement is seen within the first 2 weeks than in any other 2-week period thereafter, and more improvement is seen in the first month than in the rest of the year of follow-up. This body of data convincingly refutes the notion of "delay" in the onset of antipsychotic action and suggests an "early" onset instead. The implications of this finding for clinical decision-making, mechanisms of antipsychotic action and drug discovery are discussed.

Citing Articles

User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients.

Virelli C, Ebrahimi M, Mohiuddin A, Tomasi J, Lisoway A, Herbert D J Pers Med. 2024; 14(1).

PMID: 38248723 PMC: 10817619. DOI: 10.3390/jpm14010022.

Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets.

Grace A, Uliana D Int J Mol Sci. 2023; 24(15).

PMID: 37569748 PMC: 10418544. DOI: 10.3390/ijms241512374.

Using animal models for the studies of schizophrenia and depression: The value of translational models for treatment and prevention.

Uliana D, Zhu X, Gomes F, Grace A Front Behav Neurosci. 2022; 16:935320.

PMID: 36090659 PMC: 9449416. DOI: 10.3389/fnbeh.2022.935320.

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial.

Garrido-Sanchez L, Gomez-Revuelta M, Ortiz-Garcia de la Foz V, Pelayo-Teran J, Juncal-Ruiz M, Ruiz-Veguilla M Int J Neuropsychopharmacol. 2022; 25(11):900-911.

PMID: 35894865 PMC: 9670751. DOI: 10.1093/ijnp/pyac047.

Rethinking hospital psychiatry in Italy in light of COVID-19 experience.

Piccinelli M, Bortolaso P, Wilkinson G World J Virol. 2022; 11(1):73-81.

PMID: 35117972 PMC: 8788211. DOI: 10.5501/wjv.v11.i1.73.

References

Shen W . A history of antipsychotic drug development. Compr Psychiatry. 1999; 40(6):407-14. DOI: 10.1016/s0010-440x(99)90082-2. View

Perrault G, Depoortere R, Morel E, Sanger D, Scatton B . Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997; 280(1):73-82. View

Kuhar M, JOYCE A . Slow onset of CNS drugs: can changes in protein concentration account for the delay?. Trends Pharmacol Sci. 2001; 22(9):450-6. DOI: 10.1016/s0165-6147(00)01776-4. View

Leucht S, Pitschel-Walz G, Engel R, Kissling W . Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002; 159(2):180-90. DOI: 10.1176/appi.ajp.159.2.180. View

Tauscher J, Jones C, Remington G, Zipursky R, Kapur S . Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry. 2002; 7(3):317-21. DOI: 10.1038/sj.mp.4001009. View

Stip E . Happy birthday neuroleptics! 50 years later: la folie du doute. Eur Psychiatry. 2002; 17(3):115-9. DOI: 10.1016/s0924-9338(02)00639-9. View

Baumeister A, Francis J . Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci. 2002; 11(3):265-77. DOI: 10.1076/jhin.11.3.265.10391. View

Grunder G, Siessmeier T, Piel M, Vernaleken I, Buchholz H, Zhou Y . Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. J Nucl Med. 2003; 44(1):109-16. View

Potkin S, Saha A, Kujawa M, Carson W, Ali M, Stock E . Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60(7):681-90. DOI: 10.1001/archpsyc.60.7.681. View

10.

Correll C, Malhotra A, Kaushik S, McMeniman M, Kane J . Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003; 160(11):2063-5. DOI: 10.1176/appi.ajp.160.11.2063. View

11.

Kapur S, Mamo D . Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(7):1081-90. DOI: 10.1016/j.pnpbp.2003.09.004. View

12.

Grace A, Bunney B, Moore H, Todd C . Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997; 20(1):31-7. DOI: 10.1016/S0166-2236(96)10064-3. View

13.

Garver D, Steinberg J, McDermott B, Yao J, Ramberg J, Lewis S . Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?. Neuropsychopharmacology. 1997; 16(3):191-201. DOI: 10.1016/S0893-133X(96)00186-8. View

14.

Lehmann H, Ban T . The history of the psychopharmacology of schizophrenia. Can J Psychiatry. 1997; 42(2):152-62. DOI: 10.1177/070674379704200205. View

15.

Small J, Hirsch S, Arvanitis L, Miller B, Link C . Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997; 54(6):549-57. DOI: 10.1001/archpsyc.1997.01830180067009. View

16.

Arvanitis L, Miller B . Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997; 42(4):233-46. DOI: 10.1016/s0006-3223(97)00190-x. View

17.

Moore H, Todd C, Grace A . Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci. 1998; 18(13):5068-77. PMC: 6792547. View

18.

Daniel D, Zimbroff D, Potkin S, Reeves K, Harrigan E, Lakshminarayanan M . Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999; 20(5):491-505. DOI: 10.1016/S0893-133X(98)00090-6. View

19.

Carlsson A, Lindqvist M . EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh). 1963; 20:140-4. DOI: 10.1111/j.1600-0773.1963.tb01730.x. View

20.

Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B . Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005; 162(5):939-46. DOI: 10.1176/appi.ajp.162.5.939. View